Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of FLT180a gene therapy in haemophilia B
2017-005080-40Phase 2Unknown
- Sponsor
- Freeline Therapeutics
- Start
- Feb 2018
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of verbrinacogene setparvovec in hemophilia B (HB), sponsored by Freeline Therapeutics. Primary endpoint: Primary Safety Endpoint. Status: unknown.
02
Drugs
verbrinacogene setparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2017-005080-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005080-40.